TNF and leishmaniasis: Although there is scarce information for its recommendation, etanercep or certolizumab have been suggested as a therapeutical option instead of re-introducing other anti-TNF-α monoclonal antibodies due to its possible lower risk of reactivating leishmaniasis [65–66].